Last week, in a bold move to call for support of a rare and debilitating pulmonary disease, the Pulmonary Hypertension Association was featured on the largest screen in the world — the NASDAQ Tower on Times Square, just after ringing the opening bell for the opening of the…
News
In a recent study entitled “Blood Flow Vortices along the Main Pulmonary Artery Measured with MR Imaging for Diagnosis of Pulmonary Hypertension” the authors report that phase-contrast magnetic resonance (MR) imaging is an accurate method for diagnosing pulmonary hypertension by estimating increased mean pulmonary arterial pressure. The study…
A live webinar exploring the development of Pulmonary Fibrosis in Scleroderma patients will be hosted by Dr. Paul Wolters, Director of Biological Research at the Interstitial Lung Disease Program at University of California San Francisco (UCSF), on Thursday, November 13, 2014 at 10:00 a.m. PST. The presentation is called “Emerging Therapies in…
Patients with systemic sclerosis hoping to enroll in clinical trials investigating hematopoietic stem cell transplantation may be disqualified if they have pulmonary hypertension. During the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, reasons for turning away interested patients included pulmonary hypertension and left ventricular ejection fraction less than…
In a perfect world, equivalent responses to treatments from patients with pulmonary hypertension would make all treatment outcomes predictable and highly effective. In reality, this is not the case. However, distinguishing subtypes of pulmonary arterial hypertension can at least improve treatment outcomes by better matching patients to treatments using…
The ViScope MD – photo courtesy of HD Medical, Inc. Patients with pulmonary hypertension exhibit a number of symptoms that often lead physicians to believe the problem is confined to the lungs, making PH one of the most misdiagnosed, potentially life-threatening diseases today. Some patients…
The country’s leading source of pulmonary hypertension patient and research support, the Pulmonary Hypertension Association, is hosting the first O2 Breathe Hearts PHor Hope Gala this month. The benefit will be spearheaded by the association’s Midwest Chapter to raise funds and awareness for this rare, life-altering, and…
At the recent American College of Chest Physicians’ (ACCP) meeting, Darren Taichman, MD, PhD, executive deputy editor of the Annals of Internal Medicine, together with a colleague, presented updated information concerning diagnosis and treatment of pulmonary hypertension, based on what is known as evidence-based clinical practice guidelines.
Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who respond differently to treatment with pulmonary endarterectomy (PEA) may have differences in microvascular structure. When a team of researchers from Paris-South University and Centre Chirugical Marie Lannelongue investigated CTEPH pathogenesis in humans, they applied their findings related to microvasculature changes…
While the majority of individuals suspected of having pulmonary hypertension would prefer to receive a physical examination to confirm diagnosis, invasive right heart catheterization may still offer the most reliable indication of diagnosis. “Utility of the Physical Examination in Detecting Pulmonary Hypertension: A Mixed Methods…
A research team from the University of Alberta, led by Dr. Evengelos Michelakis, claims to have found a link between Pulmonary Hypertension, diabetes, and cancer. PAH is a disease caused by a constriction of the arteries in the lung, forcing the right heart ventricle to work intensely. This causes…
In a study entitled “A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study” published in the November issue of Annals of the Rheumatic Diseases journal, the authors sought to understand the effects of gender on the systemic sclerosis phenotype…
Recent Posts
- Access to Winrevair expands with new public coverage in Canada
- What I’ve learned in the decade since my pulmonary hypertension diagnosis
- New blood markers show promise for group 2 pulmonary hypertension
- Signaling molecule shows promise in reducing PAH severity
- Cereno cleared to launch Phase 1 trial of potential PH-ILD treatment CS014
